Results 21 to 30 of about 45,933 (222)

Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients. [PDF]

PLoS ONE, 2015
Data on the efficacy and safety of everolimus in pediatric renal transplantation compared to other immunosuppressive regimens are scarce.We therefore performed a multicenter, observational, matched cohort study over 4 years post-transplant in 35 patients
Lena Caroline Brunkhorst, Alexander Fichtner, Britta Höcker, Greta Burmeister, Thurid Ahlenstiel-Grunow, Kai Krupka, Martin Bald, Antonia Zapf, Burkhard Tönshoff, Lars Pape   +9 more
doaj   +1 more source

Use of everolimus following kidney transplantation during pregnancy: A case report and systematic review

Taiwanese Journal of Obstetrics & Gynecology, 2023
Objective: There is limited safety data on the use of everolimus during pregnancy. In this study, we present the maternal and neonatal outcomes of everolimus used throughout the course of pregnancy and conducted a systematic review of reports of ...
Pony Yee-Chee Chai, Chih Lin, Chuan-Chi Kao, Li-Mei Lin, Yi-Hua Chen, Chiao-Yin Sun   +5 more
doaj   +1 more source

Evaluation of Everolimus Activity against Mycobacterium tuberculosis Using In Vitro Models of Infection

Antibiotics, 2023
Even though Everolimus has been investigated in a phase II randomized trial as a host-directed therapy (HDT) to treat tuberculosis (TB), an oncological patient treated with Everolimus for a neuroendocrine pancreatic neoplasia developed active TB twice ...
Delia Mercedes Bianco, Flavio De Maio, Giulia Santarelli, Ivana Palucci, Alessandro Salustri, Giada Bianchetti, Giuseppe Maulucci, Franco Citterio, Maurizio Sanguinetti, Enrica Tamburrini, Michela Sali, Giovanni Delogu   +11 more
doaj   +1 more source

SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus

Cancer Biology & Therapy, 2023
Aberrant activation of the mTOR pathway is a characteristic alteration in triple-negative breast cancer, but the mTOR pathway inhibitor everolimus is not effective for the triple-negative breast cancer (TNBC) patients.
Wenwen Geng, Meiling Cao, Ke Dong, Junhua An, Haidong Gao   +4 more
doaj   +1 more source

The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease

Molecular Neurodegeneration, 2010
Background Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a CAG repeat expansion within the huntingtin gene. Mutant huntingtin protein misfolds and accumulates within neurons where it mediates its toxic effects. Promoting
Frentzel Stefan, Hoyer Daniel, Betschart Claudia, Bleckmann Dorothee, Kama Jibrin A, Dorsey Kate, Chopra Vanita, Connor Teal, Fox Jonathan H, DiFiglia Marian, Paganetti Paolo, Hersch Steven M   +11 more
doaj   +1 more source

Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population

Chinese Medical Journal, 2022
. Background:. This study aimed to reveal the treatment patterns and clinical outcomes of diverse palbociclib-based regimens in Han patients with estrogen receptor-positive (ER+) metastatic breast cancer in routine clinical practice. Methods:.
Hongnan Mo, Fei Ma, Qing Li, Pin Zhang, Peng Yuan, Jiayu Wang, Yang Luo, Ruigang Cai, Qiao Li, Binghe Xu, Xiuyuan Hao   +10 more
doaj   +1 more source

A Fatal Case of Life-Threatening Interstitial Pneumonitis Induced by Everolimus for Metastatic Renal Cell Carcinoma: A Comment about the Increased Risk of Interstitial Lung Disease in Japanese

Case Reports in Urology, 2019
We describe an 81-year-old woman with metastatic renal cell carcinoma who did not recover from life-threatening interstitial pneumonitis induced by everolimus therapy. She received everolimus due to disease progression after sunitinib, but 2 months after
Yasukiyo Murakami, Tetsuo Fujita, Yoji Wakatabe, Masatsugu Iwamura   +3 more
doaj   +1 more source

Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer

Medical Mycology Case Reports, 2014
Everolimus is an inhibitor of mammalian target of rapamycin with anti-tumour activity. While everolimus is known to cause drug-induced pneumonitis, it is rarely associated with Pneumocystis jirovecii pneumonia (PJP).
Kelvin Teck-Hong Kuik, Jason Trubiano, Leon J. Worth, Nur-shirin Harun, Daniel Steinfort, Douglas Johnson   +5 more
doaj   +1 more source

Impact of De Novo Everolimus-Based Immunosuppression on Incisional Complications in Heart Transplantation

, 2012
Background. The mammalian target of rapamycin inhibitor sirolimus has been associated with an increased incidence of wound-healing complications after de novo heart transplantation.
王水深, Zuckermann, Andreas; Arizon, Jose M.; Dong, Gaohong; Eisen, Howard J.; Kobashigawa, Jon; Lehmkuhl, Hans; Ross, Heather; Pelligrini, Carlo; Wang, Shoei-Shen; Barten, Markus J.   +1 more
core   +1 more source

Exploring the Protective Role of Everolimus in Preventing Pentylenetetrazole-Triggered Injury in Hippocampal Neurons Using the HT-22 Cell Line

Cumhuriyet Science Journal
This study aimed to explore the neuroprotective properties of everolimus and its association with oxidative stress. The HT-22 hippocampal neuronal cell line was utilized as the in vitro model.
Fatih Yulak, İrem Cinaz
doaj   +1 more source